June 6, 2026 06:44 AM EDT R&D Roche wants the best of both worlds with amylin-incretin combo strategy Elizabeth Cairns Senior biopharma journalist Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
83 words · extracted 1mo agoread original ↗
comments(0)
5-min edit window · permanent after that